| 0 (0%) | 12-26 20:16 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.5 | 1-year : | 2.96 |
| Resists | First : | 2.14 | Second : | 2.53 |
| Pivot price | 2.03 |
|||
| Supports | First : | 1.5 | Second : | 1.25 |
| MAs | MA(5) : | 1.87 |
MA(20) : | 2  |
| MA(100) : | 1.56 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 18.2 |
D(3) : | 20.5 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 3.39 | Low : | 0.79 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OTLK ] has closed above bottom band by 18.3%. Bollinger Bands are 22.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.95 - 1.96 | 1.96 - 1.98 |
| Low: | 1.76 - 1.77 | 1.77 - 1.78 |
| Close: | 1.8 - 1.82 | 1.82 - 1.84 |
Fri, 26 Dec 2025
Outlook Therapeutics Grants Stock Options to New Employees as Part of Inducement Package - Quiver Quantitative
Fri, 26 Dec 2025
Outlook Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Fri, 26 Dec 2025
Biotech offers stock options to lure two new hires at $2.01 a share - Stock Titan
Mon, 22 Dec 2025
Oncobiologics (NASDAQ:OTLK) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says - MarketBeat
Mon, 22 Dec 2025
New Analyst Forecast: $OTLK Given $10 Price Target - Quiver Quantitative
Mon, 22 Dec 2025
Ascendiant Capital Maintains Outlook Therapeutics (OTLK) Buy Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 2.909e+007 (%) |
| Held by Institutions | 36.3 (%) |
| Shares Short | 2,400 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.251e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 46.2 % |
| Return on Equity (ttm) | -130.7 % |
| Qtrly Rev. Growth | 1.51e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.24278e+008 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.39 |
| Dividend | 0 |
| Forward Dividend | 3.35e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|